Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al
Int J Technol Assess Health Care
.
2007 Summer;23(3):397-401; author reply 401-4.
doi: 10.1017/s0266462307071012.
Authors
Christopher McCabe
,
Aki Tsuchiya
,
Karl Claxton
,
James Raftery
PMID:
17579945
DOI:
10.1017/s0266462307071012
No abstract available
Publication types
Comment
Letter
MeSH terms
Cost-Benefit Analysis
Europe
Health Policy
Humans
Orphan Drug Production / economics*
Technology Assessment, Biomedical*
United States